CIT 2026 Concludes: China's IABP System and TeleVad Take Center Stage

The 24th Annual Scientific Session of the Chinese Society of Interventional Cardiology (CIT 2026) recently concluded successfully in Beijing. The congress brought together leading experts and scholars from both domestic and international arenas, along with primary-level cardiovascular healthcare workers from across the country. The event focused on cutting-edge interventional cardiology technologies and aimed to accelerate the translation of academic innovation into clinical practice.

A Breakthrough: Domestic IABP "Device + Consumables" Full-Chain Solution

As the most widely used mechanical circulatory assist device, the intra-aortic balloon pump (IABP) plays a vital role in interventional cardiology therapy. To highlight this, the congress specially organized a symposium titled "Domestic IABP 'Device + Consumables' Full-Chain Solution," inviting several medical experts to engage in in-depth discussions on China’s first homegrown IABP device and its配套 balloon consumables, independently developed by Tongling Bionic.

The symposium was co-chaired by Professor Song Xiantao from Beijing Friendship Hospital, Capital Medical University; Professor Song Lei from Fuwai Hospital, Chinese Academy of Medical Sciences; Professor Sun Yihong from Beijing Anzhen Hospital, Capital Medical University; and Professor Wang Yanfu from Aviation General Hospital.

Prior to the symposium, attending experts observed and experienced Tongling Bionic’s TL-IABP-100 device and TL-IAB series balloon consumables on-site, offering positive feedback. As China’s first independently developed IABP device and balloon consumables, the products have achieved world-class performance in the precision, safety, and efficacy of counterpulsation therapy, successfully breaking the long-standing foreign monopoly in this field.

During the symposium, speakers included Professor Zhang Jun, Professor Zhu Fasheng, and Deputy Chief Nurse Yang Yang from Fuwai Hospital, Chinese Academy of Medical Sciences; Professor Zhao Jingtao from Hebei Yanda Hospital; Dr. Yang Dongsheng from Beijing Aerospace Center Hospital; and Wan Chuanyang, R&D Supervisor at Tongling Bionic. They systematically shared insights on IABP operation procedures, usage management, routine nursing care, balloon insertion, typical cases, complication prevention, and technological advancements.

Cutting-Edge Technology: TeleVad Interventional Ventricular Assist Device

In addition, the congress showcased another innovative product from Tongling Bionic — the TeleVad interventional ventricular assist device. This technology is regarded as a revolutionary advancement in the treatment of critical cardiovascular emergencies in recent years. Its core principle involves inserting a micro-axial pump into the patient’s heart via an interventional approach, actively aspirating blood to unload cardiac workload while enhancing perfusion to the coronary arteries and vital organs, offering a new solution for short-to-medium-term circulatory support.

Tongling Bionic has now launched the TeleVad series, including models such as the P50, P35, and RP, covering left and right ventricular support and varying flow rate requirements. The products adopt a proven, safe, and reliable motor-embedded design. Through extensive theoretical calculations, modeling and simulation, and experimental research, the company has achieved a series of breakthroughs in key technologies such as hemodynamics and hemocompatibility optimization, as well as in the design and manufacturing of core components including micro-motors, low-hemolysis impellers, and novel anticoagulation cooling systems. With fully independent intellectual property rights, the TeleVad series has been selected for a National Key R&D Program of China and has entered the Innovative Medical Device Special Review Process of China’s National Medical Products Administration (NMPA).